3Biotech has announced a new collaboration with Cartelis, a data and CRM operational consulting firm, to explore innovative ways to enhance value for clients in the pharmaceutical and biotech sectors. This strategic partnership will harness the power of data and artificial intelligence (AI) to streamline Chemistry, Manufacturing, and Controls (CMC) processes, delivering more efficient, cost-effective solutions for drug development.
The collaboration has already yielded results, with a comprehensive data and AI assessment identifying several key opportunities to optimise 3Biotech's operations. These innovations are set to accelerate project timelines, enhance risk management, and benefit 3Biotech’s clients in the biotech and pharmaceutical industries significantly.
Olivier Favre-Bulle, Founder and CEO of 3Biotech, expressed his excitement about the partnership, stating: “At 3Biotech, innovation is central to everything we do. By integrating AI into our CMC processes, we’re helping our clients make smarter, faster decisions and also accelerating the development of safe and effective drug candidates. The collaboration with Cartelis is a game-changer, and we are already seeing a positive impact.”
The partnership is focused on three main areas of innovation:
Data-Driven Insights with Machine Learning: Using AI to extract actionable insights from complex datasets, enabling better decision-making.
Predictive Modeling for Process Optimization: Leveraging machine learning models to optimize drug development processes, improving efficiency and reducing costs.
Accelerating Time-to-Clinic: Streamlining timelines to bring drug candidates to clinical trials faster, benefiting patients and developers.
Bpifrance, a public investment bank supporting innovation in France, is backing this collaboration, enabling both companies to explore ambitious digital transformation projects. As Favre-Bulle concludes: “Together with Cartelis and with the support of Bpifrance, we’re building solutions that deliver real value for our clients - not just for today but for the future of drug development.”
This partnership underscores 3Biotech's commitment to advancing drug development through innovation, ensuring that its clients can stay ahead in a competitive, fast-evolving market.